Mana Therapeutics, Inc.

EDIFY

Manufacturing of cell therapy platforms for others that trains T-cells to target multiple tumor associated antigens;Pharmaceutical preparations for the treatment of cancer that educate immune cells, without viral, non-viral or other genetic modifications, to manufacture multi-tumor associated antigen T-cells;Reagents for scientific and research use, namely, for use in the manufacturing process of cell therapy platforms to train T-cells to target multiple tumor associated antigens; biochemical preparations in the form of biochemical platforms for scientific purposes, namely, for the manufacturing of cell therapy that trains T-cells to target multiple tumor associated antigens;Platform as a service (PAAS) featuring biological computer software platforms for developing drug products to improve ability to target tumor cells; Platform as a service (PAAS) featuring biological computer software platforms for research and development of pharmaceuticals for use with cell therapy to manufacture tumor-targeted T-cell products and target tumor-specific antigens without genetic modification;

EDUCATING IMMUNE CELLS. ELIMINATING CANCER.

Pharmaceutical products and drugs for the treatment of cancerous hematologic and solid tumors;

EDUCATING IMMUNE CELLS. ELIMINATING CANCER.

Medical and scientific research services in the areas of cancer and other diseases;

MANA MEDIA

Pharmaceutical preparations, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;Cell media for use in the manufacture of pharmaceutical preparations for activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;MEDIA;

MANA MIX

Pharmaceutical preparations, namely, Synthetic tumor antigen peptide mixes for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;Synthetic tumor antigen peptide mixes for use in the manufacture of pharmaceutical preparations for activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;MIX;

MANA THERAPEUTICS

Pharmaceutical products and drugs for the treatment of cancerous hematologic and solid tumors;THERAPEUTICS;

MANA THERAPEUTICS

THERAPEUTICS;Medical and scientific research services in the areas of cancer and other diseases;

MANAMATCH

Pharmaceutical preparations for treating cancer that assist in evaluating and matching common Human Leukocyte Antigen (HLA) with antigen reactivity to potential cancer patients by using predetermined parameters to optimize efficacy and safety;MANA MATCH;Development of methodologies in the field of medicine to optimize a match between cell product and patient, matching common Human Leukocyte Antigen (HLA) with antigen reactivity to potential cancer patients in order to enhance the efficacy of Human Leukocyte Antigen (HLA) and specific antigen;

MANAMEDIA

Pharmaceutical preparations, namely, Cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;MANA MEDIA;Cell media for use in the manufacture of pharmaceutical preparations for activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;

MANAMIX

Pharmaceutical preparations, namely, Synthetic tumor antigen peptide mixes for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;MANA MIX;Synthetic tumor antigen peptide mixes for use in the manufacture of pharmaceutical preparations for activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers;